Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The anticipated decline in the biotech industry's ability to raise capital from public investors and an accompanying slump in biotech markets materialized in 2016, but all is not gloom and doom.
Our annual survey highlights several academic startups developing immunotherapies as well as ventures focusing on microbiomes, proteostasis, integrin biology, nucleic acid delivery and subcellular imaging.
Interest in cancer vaccines is being reignited by a greater understanding of tumor immunology and the potential of combining immunogens with new breakthrough immunotherapies.
Immuno-oncology was hotly pursued by investors in 2015, along with drug delivery platforms. In the agbiotech world, a systems biology company set up shop.
Current regulatory regimes for genetically engineered crops fail to use a scientifically defensible approach or tailor the degree of regulatory review to the level of actual hazard or risk. We describe a rational way forward.
Authors of some of the most highly cited Nature Biotechnology nonbiomedical papers from the past 20 years discuss their work and challenges for their fields.
Authors of some of the most highly cited Nature Biotechnology biomedical papers from the past 20 years discuss their work and challenges for their fields.
US biotech sector revenue is estimated to have grown on average >10% each year over the past decade—much faster than the rest of the economy. A more comprehensive assessment of biotech's economic contribution, however, will require improved data collection, classification and analysis.
Nature Biotechnology asks a selection of researchers about the most exciting frontier in their field and the most needed technologies for advancing knowledge and applications.
Although a few arable crops and agronomic traits will likely dominate commercial varieties for the foreseeable future, with many being stacked together, more quality traits and specialty crops are being introduced into the pipeline.